BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rimassa L, Danesi R, Pressiani T, Merle P. Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev 2019;77:20-8. [PMID: 31195212 DOI: 10.1016/j.ctrv.2019.05.004] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 16.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhou X, Li TM, Luo JZ, Lan CL, Wei ZL, Fu TH, Liao XW, Zhu GZ, Ye XP, Peng T. CYP2C8 Suppress Proliferation, Migration, Invasion and Sorafenib Resistance of Hepatocellular Carcinoma via PI3K/Akt/p27kip1 Axis. J Hepatocell Carcinoma 2021;8:1323-38. [PMID: 34765572 DOI: 10.2147/JHC.S335425] [Reference Citation Analysis]
2 Celsa C, Giuffrida P, Giacchetto CM, Stornello C, Rancatore G, Grova M, Ricciardi MR, Rizzo S, Cammà C, Cabibbo G. Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma. Liver Cancer International 2021;2:82-95. [DOI: 10.1002/lci2.38] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Rao VU, Reeves DJ, Chugh AR, O'Quinn R, Fradley MG, Raghavendra M, Dent S, Barac A, Lenihan D. Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents: JACC State-of-the-Art Review. J Am Coll Cardiol 2021;77:2693-716. [PMID: 34045027 DOI: 10.1016/j.jacc.2021.04.009] [Reference Citation Analysis]
4 Kudo M, Galle PR, Llovet JM, Finn RS, Vogel A, Motomura K, Assenat E, Merle P, Brandi G, Daniele B, Okusaka T, Tomášek J, Borg C, Dadduzio V, Morimoto M, Pracht M, Jen MH, Drove Ubreva N, Widau RC, Shinozaki K, Yoshikawa R, Zhu AX. Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. Liver Int 2020;40:2008-20. [PMID: 32279446 DOI: 10.1111/liv.14462] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
5 Motzer RJ, Taylor MH, Evans TRJ, Okusaka T, Glen H, Lubiniecki GM, Dutcus C, Smith AD, Okpara CE, Hussein Z, Hayato S, Tamai T, Makker V. Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies. Expert Rev Anticancer Ther 2022. [PMID: 35260027 DOI: 10.1080/14737140.2022.2039123] [Reference Citation Analysis]
6 Song SS, Ying JF, Zhang YN, Pan HY, He XL, Hu ZM, Wang HJ, Dou XB, Mou XZ. High expression of FOXO3 is associated with poor prognosis in patients with hepatocellular carcinoma. Oncol Lett 2020;19:3181-8. [PMID: 32256814 DOI: 10.3892/ol.2020.11430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
7 Wiest NE, Tzou KS, Olson MT, Herchko SM, Bajalia EM, Thiel DD, Lou Y, Zhao Y, Manochakian R. Crizotinib-associated renal cyst development may be associated with prolonged progression-free survival in patients with ALK-positive non-small-cell lung cancer: Case report and review of the literature. Clin Case Rep 2021;9:e04278. [PMID: 34136235 DOI: 10.1002/ccr3.4278] [Reference Citation Analysis]
8 Pereira RA, Pires ADRA, Echevarria A, Sousa-Pereira D, Noleto GR, Suter Correia Cadena SM. The toxicity of 1,3,4-thiadiazolium mesoionic derivatives on hepatocarcinoma cells (HepG2) is associated with mitochondrial dysfunction. Chem Biol Interact 2021;349:109675. [PMID: 34563518 DOI: 10.1016/j.cbi.2021.109675] [Reference Citation Analysis]
9 Zhou Q, Zhou Q, Liu Q, He Z, Yan Y, Lin J, Chen Z, He C, Mao K, Wang J, Zhou Z, Xiao Z, Zhang J. PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK. Theranostics 2020;10:10345-59. [PMID: 32929353 DOI: 10.7150/thno.42069] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Takahashi S. Fatigue and its management in cancer patients undergoing VEGFR-TKI therapy. Expert Opin Drug Saf 2021;:1-10. [PMID: 34461788 DOI: 10.1080/14740338.2021.1969360] [Reference Citation Analysis]
11 Rapoport BL, Cooksley T, Johnson DB, Anderson R. Supportive care for new cancer therapies. Curr Opin Oncol 2021;33:287-94. [PMID: 33756517 DOI: 10.1097/CCO.0000000000000736] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Rimini M, Shimose S, Lonardi S, Tada T, Masi G, Iwamoto H, Lai E, Burgio V, Hiraoka A, Ishikawa T, Soldà C, Shirono T, Vivaldi C, Takaguchi K, Shimada N, Astara G, Koga H, Nouso K, Joko K, Torimura T, Hiasa Y, Salani F, Scartozzi M, Cascinu S, Casadei-Gardini A. Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study. Hepatol Res 2021;51:1229-41. [PMID: 34591334 DOI: 10.1111/hepr.13718] [Reference Citation Analysis]
13 Wei Y, Wang Y, Liu N, Qi R, Xu Y, Li K, Feng Y, Shi B. A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model. Front Pharmacol 2022;12:820446. [DOI: 10.3389/fphar.2021.820446] [Reference Citation Analysis]
14 Hassan YA, Helmy MW, Ghoneim AI. Combinatorial antitumor effects of amino acids and epigenetic modulations in hepatocellular carcinoma cell lines. Naunyn Schmiedebergs Arch Pharmacol 2021;394:2245-57. [PMID: 34415354 DOI: 10.1007/s00210-021-02140-z] [Reference Citation Analysis]
15 Zhao F, Qin J, Liang Y, Zhou R. Exploring anti-liver cancer targets and mechanisms of oxyresveratrol: in silico and verified findings. Bioengineered 2021. [PMID: 34592904 DOI: 10.1080/21655979.2021.1985328] [Reference Citation Analysis]
16 Trojan J. Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives. Drugs 2020;80:1203-10. [PMID: 32671719 DOI: 10.1007/s40265-020-01361-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
17 Zhang Q, Xu X, Wu M, Qin T, Wu S, Liu H. MiRNA Polymorphisms and Hepatocellular Carcinoma Susceptibility: A Systematic Review and Network Meta-Analysis. Front Oncol 2020;10:562019. [PMID: 33542895 DOI: 10.3389/fonc.2020.562019] [Reference Citation Analysis]
18 Lal LS, Aly A, Le LB, Peckous S, Seal B, Teitelbaum A. Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims study. Cancer Rep (Hoboken) 2021;:e1504. [PMID: 34494389 DOI: 10.1002/cnr2.1504] [Reference Citation Analysis]
19 Mcgregor B, Mortazavi A, Cordes L, Salabao C, Vandlik S, Apolo AB. Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review. Cancer Treatment Reviews 2022;103:102333. [DOI: 10.1016/j.ctrv.2021.102333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Qiu X, Li M, Wu L, Xin Y, Mu S, Li T, Song K. Severe Fatigue is an Important Factor in the Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Cancer Manag Res 2020;12:7983-92. [PMID: 32943932 DOI: 10.2147/CMAR.S233448] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Lv Y, Wang Y, Zheng X, Liang G. Reveal the interaction mechanism of five old drugs targeting VEGFR2 through computational simulations. J Mol Graph Model 2020;96:107538. [PMID: 31981898 DOI: 10.1016/j.jmgm.2020.107538] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Qing X, Xu W, Zong J, Du X, Peng H, Zhang Y. Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. Biomark Res 2021;9:64. [PMID: 34419152 DOI: 10.1186/s40364-021-00319-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Li G, Zhao M, Zhao L. Development and validation of an UPLC-MS/MS method for simultaneous determination of fifteen targeted anti-cancer drugs in human plasma and its application in therapeutic drug monitoring. Journal of Pharmaceutical and Biomedical Analysis 2021. [DOI: 10.1016/j.jpba.2021.114517] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Schwartz G, Darling JO, Mindo M, Damicis L. Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma. Target Oncol 2020;15:549-65. [PMID: 32770441 DOI: 10.1007/s11523-020-00736-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
25 Meriggi F, Graffeo M. Clinical Characterisation and Management of the Main Treatment-Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis. Cancers (Basel) 2021;13:584. [PMID: 33540870 DOI: 10.3390/cancers13030584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Du D, Liu C, Qin M, Zhang X, Xi T, Yuan S, Hao H, Xiong J. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm Sin B 2022;12:558-80. [PMID: 35256934 DOI: 10.1016/j.apsb.2021.09.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
27 Yanagihara T, Matsumoto K, Yoneda R, Egashira A, Mannoji H, Watanabe H, Hanaoka K, Nakayama Y, Ogo N, Inutsuka Y, Asoh T, Kohashi K, Kinoshita I, Oda Y, Maeyama T. Lenvatinib for poorly differentiated carcinoma of the anterior mediastinum. Respir Med Case Rep 2021;33:101477. [PMID: 34401310 DOI: 10.1016/j.rmcr.2021.101477] [Reference Citation Analysis]
28 Rimassa L, Personeni N, Czauderna C, Foerster F, Galle P. Systemic treatment of HCC in special populations. J Hepatol 2021;74:931-43. [PMID: 33248171 DOI: 10.1016/j.jhep.2020.11.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
29 Li Q, Xiong DL, Wang H, Jin WL, Ma YY, Fan XM. High Expression of SLC41A3 Correlates with Poor Prognosis in Hepatocellular Carcinoma. Onco Targets Ther 2021;14:2975-88. [PMID: 33981147 DOI: 10.2147/OTT.S296187] [Reference Citation Analysis]
30 Cheng M, Yang F, Liu J, Yang D, Zhang S, Yu Y, Jiang S, Dong M. Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies. Front Cardiovasc Med 2021;8:758010. [PMID: 34869670 DOI: 10.3389/fcvm.2021.758010] [Reference Citation Analysis]
31 Tanaka H, Horioka K, Hasebe T, Sawada K, Nakajima S, Konishi H, Isozaki S, Goto M, Fujii Y, Kamikokura Y, Ogawa K, Nishikawa Y. Treatment of hepatocellular carcinoma with autologous platelets encapsulating sorafenib or lenvatinib: A novel therapy exploiting tumor‐platelet interactions. Intl Journal of Cancer. [DOI: 10.1002/ijc.33915] [Reference Citation Analysis]
32 Makker V, Taylor MH, Oaknin A, Casado Herraez A, Orlowski R, Dutta L, Ren M, Zale M, O'Malley DM. Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab. Oncologist 2021;26:e1599-608. [PMID: 34190370 DOI: 10.1002/onco.13883] [Reference Citation Analysis]
33 Yen CC, Yen CJ. Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. Expert Opin Drug Saf 2021;:1-10. [PMID: 34668832 DOI: 10.1080/14740338.2022.1995353] [Reference Citation Analysis]
34 Ptinopoulou AG, Sprangers B. Tyrosine kinase inhibitor-induced hypertension-marker of anti-tumour treatment efficacy or cardiovascular risk factor? Clin Kidney J 2021;14:14-7. [PMID: 33564402 DOI: 10.1093/ckj/sfaa174] [Reference Citation Analysis]
35 Liu F, Qin L, Liao Z, Song J, Yuan C, Liu Y, Wang Y, Xu H, Zhang Q, Pei Y, Zhang H, Pan Y, Chen X, Zhang Z, Zhang W, Zhang B. Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma. Exp Hematol Oncol 2020;9:10. [PMID: 32509418 DOI: 10.1186/s40164-020-00165-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
36 Fu Y, Liu S, Zeng S, Shen H. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:396. [PMID: 31500650 DOI: 10.1186/s13046-019-1396-4] [Cited by in Crossref: 76] [Cited by in F6Publishing: 82] [Article Influence: 25.3] [Reference Citation Analysis]
37 Lin H, Zhang R, Wu W, Lei L. Comprehensive network analysis of the molecular mechanisms associated with sorafenib resistance in hepatocellular carcinoma. Cancer Genet 2020;245:27-34. [PMID: 32559715 DOI: 10.1016/j.cancergen.2020.04.076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
38 Campani C, Capone M, Liotta F, Arena U, Adotti V, Di Bonaventura C, Aburas S, Colagrande S, Calistri L, Annunziato F, Marra F. Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma. Dig Liver Dis 2021:S1590-8658(21)00850-1. [PMID: 34876355 DOI: 10.1016/j.dld.2021.11.010] [Reference Citation Analysis]
39 Fang T, Lu Q. A-kinase interacting protein 1 (AKIP1) associates with advanced overall disease condition, tumor properties, and unfavorable prognosis in hepatocellular carcinoma patients. J Clin Lab Anal 2020;34:e23213. [PMID: 32133702 DOI: 10.1002/jcla.23213] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
40 Maggiore U, Palmisano A, Buti S, Claire Giudice G, Cattaneo D, Giuliani N, Fiaccadori E, Gandolfini I, Cravedi P. Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients? Transpl Int 2021. [PMID: 34555228 DOI: 10.1111/tri.14115] [Reference Citation Analysis]
41 Xie L, Xu J, Guo W, Wang Z, Yao Y, Li J, Lin J, Xiao J, Yu X, Zhang W, Cai Z, Hua Y, Chen J, Shao Z, Wu D, Wu S, Tu Z, Zhang X. Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience. Front Oncol 2021;11:696865. [PMID: 34367981 DOI: 10.3389/fonc.2021.696865] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Wu YL, Smit EF, Bauer TM. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies. Cancer Treat Rev 2021;95:102173. [PMID: 33740553 DOI: 10.1016/j.ctrv.2021.102173] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Xiu Z, Zhu Y, Han J, Li Y, Yang X, Yang G, Song G, Li S, Li Y, Cheng C, Li Y, Fang J, Li X, Jin N. Caryophyllene Oxide Induces Ferritinophagy by Regulating the NCOA4/FTH1/LC3 Pathway in Hepatocellular Carcinoma. Front Pharmacol 2022;13:930958. [DOI: 10.3389/fphar.2022.930958] [Reference Citation Analysis]
44 Tian LL, Qian B, Jiang XH, Liu YS, Chen T, Jia CY, Zhou YL, Liu JB, Ma YS, Fu D, Ding ST. MicroRNA-497-5p Is Downregulated in Hepatocellular Carcinoma and Associated with Tumorigenesis and Poor Prognosis in Patients. Int J Genomics 2021;2021:6670390. [PMID: 33816607 DOI: 10.1155/2021/6670390] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Bang YH, Lee C, Yoo C, Chon HJ, Hong M, Kang B, Kim H, Park SR, Choi W, Choi J, Lee D, Shim JH, Kim KM, Lim Y, Lee HC, Ryu M, Ryoo B. Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis. Ther Adv Med Oncol 2022;14:175883592210979. [DOI: 10.1177/17588359221097934] [Reference Citation Analysis]
46 Muzellec L, Bourien H, Edeline J. Patients' Experience of Systemic Treatment of Hepatocellular Carcinoma: A Review of the Impact on Quality of Life. Cancers (Basel) 2021;14:179. [PMID: 35008343 DOI: 10.3390/cancers14010179] [Reference Citation Analysis]
47 Gao Y, Liu P, Shi R. Anlotinib as a molecular targeted therapy for tumors. Oncol Lett 2020;20:1001-14. [PMID: 32724339 DOI: 10.3892/ol.2020.11685] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
48 Fu D, Shi Y, Liu JB, Wu TM, Jia CY, Yang HQ, Zhang DD, Yang XL, Wang HM, Ma YS. Targeting Long Non-coding RNA to Therapeutically Regulate Gene Expression in Cancer. Mol Ther Nucleic Acids 2020;21:712-24. [PMID: 32771923 DOI: 10.1016/j.omtn.2020.07.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
49 Ma YS, Liu JB, Wu TM, Fu D. New Therapeutic Options for Advanced Hepatocellular Carcinoma. Cancer Control 2020;27:1073274820945975. [PMID: 32799550 DOI: 10.1177/1073274820945975] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
50 Wong LS, Wong CM. Decoding the Roles of Long Noncoding RNAs in Hepatocellular Carcinoma. Int J Mol Sci 2021;22:3137. [PMID: 33808647 DOI: 10.3390/ijms22063137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Vogel A, Rimassa L, Sun HC, Abou-Alfa GK, El-Khoueiry A, Pinato DJ, Sanchez Alvarez J, Daigl M, Orfanos P, Leibfried M, Blanchet Zumofen MH, Gaillard VE, Merle P. Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis. Liver Cancer 2021;10:240-8. [PMID: 34239810 DOI: 10.1159/000515302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Sardeli C, Zarogoulidis P, Romanidis K, Oikonomou P, Sapalidis K, Huang H, Bai C, Hohenforst-Schmidt W, Tsakiridis K, Zaric B, Perin B, Ioannidis A, Baka S, Drevelegas K, Kosmidou M, Kosmidis C. Acute pneumothorax due to immunotherapy administration in non-small cell lung cancer. Respir Med Case Rep 2020;31:101258. [PMID: 33145157 DOI: 10.1016/j.rmcr.2020.101258] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Mahmoud K, Swidan S, El-nabarawi M, Teaima M. Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01309-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
54 Cao L, Zhu YQ, Wu ZX, Wang GX, Cheng HW. Engineering nanotheranostic strategies for liver cancer. World J Gastrointest Oncol 2021; 13(10): 1213-1228 [PMID: 34721763 DOI: 10.4251/wjgo.v13.i10.1213] [Reference Citation Analysis]
55 Wei Q, Zhou H, Hou X, Liu X, Chen S, Huang X, Chen Y, Liu M, Duan Z. Current status of and barriers to the treatment of advanced-stage liver cancer in China: a questionnaire-based study from the perspective of doctors. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02425-4] [Reference Citation Analysis]
56 Saito K, Fujii H, Kono K, Hirabayashi K, Yamatani S, Watanabe K, Goto S, Komatsu S, Fukumoto T, Nishi S. Changes in blood pressure during treatment with the tyrosine kinase inhibitor lenvatinib. Clin Kidney J 2021;14:325-31. [PMID: 33564435 DOI: 10.1093/ckj/sfaa137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: An EASL position paper. J Hepatol 2021:S0168-8278(21)01903-6. [PMID: 34256065 DOI: 10.1016/j.jhep.2021.07.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
58 Huang KK, Han SS, He LY, Yang LL, Liang BY, Zhen QY, Zhu ZB, Zhang CY, Li HY, Lin Y. Combination therapy (toripalimab and lenvatinib)-associated toxic epidermal necrolysis in a patient with metastatic liver cancer: A case report. World J Clin Cases 2022; 10(11): 3478-3484 [DOI: 10.12998/wjcc.v10.i11.3478] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Kaur J, Tuler S, Dasanu CA. Sustained erythrocytosis due to the use of Lenvatinib. J Oncol Pharm Pract 2021;:10781552211039108. [PMID: 34665694 DOI: 10.1177/10781552211039108] [Reference Citation Analysis]
60 Rapposelli IG, Tada T, Shimose S, Burgio V, Kumada T, Iwamoto H, Hiraoka A, Niizeki T, Atsukawa M, Koga H, Hirooka M, Torimura T, Iavarone M, Tortora R, Campani C, Lonardi S, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Giuseppe Foschi F, Silletta M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Tani J, Nakamura S, Nouso K, Tsutsui A, Nagano T, Tanaka T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Rimini M, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. Liver Int 2021;41:2997-3008. [PMID: 34250737 DOI: 10.1111/liv.15014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 Xia W, Peng T, Guan R, Zhou Y, Zeng C, Lin Y, Wu Z, Tan H. Development of a novel prognostic nomogram for the early recurrence of liver cancer after curative hepatectomy. Ann Transl Med 2021;9:1541. [PMID: 34790747 DOI: 10.21037/atm-21-4837] [Reference Citation Analysis]
62 D'Alessio A, Cammarota A, Prete MG, Pressiani T, Rimassa L. The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together. Curr Opin Oncol 2021;33:386-94. [PMID: 33867478 DOI: 10.1097/CCO.0000000000000744] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Rithanya P, Ezhilarasan D. Sodium Valproate, a Histone Deacetylase Inhibitor, Provokes Reactive Oxygen Species-Mediated Cytotoxicity in Human Hepatocellular Carcinoma Cells. J Gastrointest Cancer 2021;52:138-44. [PMID: 32006341 DOI: 10.1007/s12029-020-00370-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
64 Hou J, Xiao Y, Huang J, Jiang X, Jiang K, Li X, Xu L, Chen M. Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma. Front Pharmacol 2022;13:917384. [DOI: 10.3389/fphar.2022.917384] [Reference Citation Analysis]
65 Xu X, Ding Y, Pan T, Gao F, Huang X, Sun Q. CT-Guided 125I Brachytherapy in the Treatment of Hepatocellular Carcinoma Refractory to Conventional Transarterial Chemoembolization: A Pilot Study. Cancer Manag Res 2021;13:3317-26. [PMID: 33883943 DOI: 10.2147/CMAR.S305422] [Reference Citation Analysis]
66 D'Alessio A, Rimassa L, Cortellini A, Pinato DJ. PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. J Hepatocell Carcinoma 2021;8:887-97. [PMID: 34386437 DOI: 10.2147/JHC.S284440] [Reference Citation Analysis]
67 Chen F, Fang Y, Zhao R, Le J, Zhang B, Huang R, Chen Z, Shao J. Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma. Eur J Med Chem 2019;179:916-35. [PMID: 31306818 DOI: 10.1016/j.ejmech.2019.06.070] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
68 Ma YS, Chu KJ, Ling CC, Wu TM, Zhu XC, Liu JB, Yu F, Li ZZ, Wang JH, Gao QX, Yi B, Wang HM, Gu LP, Li L, Tian LL, Shi Y, Jiang XQ, Fu D, Zhang XW. Long Noncoding RNA OIP5-AS1 Promotes the Progression of Liver Hepatocellular Carcinoma via Regulating the hsa-miR-26a-3p/EPHA2 Axis. Mol Ther Nucleic Acids 2020;21:229-41. [PMID: 32585630 DOI: 10.1016/j.omtn.2020.05.032] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
69 Rinaldi L, Vetrano E, Rinaldi B, Galiero R, Caturano A, Salvatore T, Sasso FC. HCC and Molecular Targeting Therapies: Back to the Future. Biomedicines 2021;9:1345. [PMID: 34680462 DOI: 10.3390/biomedicines9101345] [Reference Citation Analysis]
70 Tripodi F, Badone B, Vescovi M, Milanesi R, Nonnis S, Maffioli E, Bonanomi M, Gaglio D, Tedeschi G, Coccetti P. Methionine Supplementation Affects Metabolism and Reduces Tumor Aggressiveness in Liver Cancer Cells. Cells 2020;9:E2491. [PMID: 33207837 DOI: 10.3390/cells9112491] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Li K, Xiao K, Zhu S, Wang Y, Wang W. Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges. Front Pharmacol 2022;13:889799. [DOI: 10.3389/fphar.2022.889799] [Reference Citation Analysis]
72 Liu L, Liu Z, Gao J, Liu X, Weng S, Guo C, Hu B, Wang Z, Zhang J, Shi J, Guo W, Zhang S. CD8+ T cell trajectory subtypes decode tumor heterogeneity and provide treatment recommendations for hepatocellular carcinoma. Front Immunol 2022;13:964190. [DOI: 10.3389/fimmu.2022.964190] [Reference Citation Analysis]
73 Cui Y, Li Y, Li X, Fan L, He X, Fu Y, Dong Z. A Simple UPLC/MS-MS Method for Simultaneous Determination of Lenvatinib and Telmisartan in Rat Plasma, and Its Application to Pharmacokinetic Drug-Drug Interaction Study. Molecules 2022;27:1291. [PMID: 35209080 DOI: 10.3390/molecules27041291] [Reference Citation Analysis]
74 Iwamoto H, Suzuki H, Shimose S, Niizeki T, Nakano M, Shirono T, Okamura S, Noda Y, Kamachi N, Nakamura T, Masuda A, Sakaue T, Tanaka T, Nakano D, Sakai M, Yamaguchi T, Kuromatsu R, Koga H, Torimura T. Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability toward Adverse Events. Cancers (Basel) 2020;12:E1010. [PMID: 32325921 DOI: 10.3390/cancers12041010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
75 Hsu C, Rimassa L, Sun HC, Vogel A, Kaseb AO. Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. Ther Adv Med Oncol 2021;13:17588359211031141. [PMID: 34377156 DOI: 10.1177/17588359211031141] [Reference Citation Analysis]
76 Wang Y, Su GF, Huang ZX, Wang ZG, Zhou PJ, Fan JL, Wang YF. Cepharanthine hydrochloride induces mitophagy targeting GPR30 in hepatocellular carcinoma (HCC). Expert Opin Ther Targets 2020;24:389-402. [PMID: 32106726 DOI: 10.1080/14728222.2020.1737013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
77 Guo J, Zeng H, Liu Y, Shi X, Liu Y, Liu C, Chen Y. Multicomponent thermosensitive lipid complexes enhance desmoplastic tumor therapy through boosting anti-angiogenesis and synergistic strategy. Int J Pharm 2021;601:120533. [PMID: 33781886 DOI: 10.1016/j.ijpharm.2021.120533] [Reference Citation Analysis]
78 Tovoli F, Dadduzio V, De Lorenzo S, Rimassa L, Masi G, Iavarone M, Marra F, Garajova I, Brizzi MP, Daniele B, Trevisani F, Messina C, Di Clemente F, Pini S, Cabibbo G, Granito A, Rizzato MD, Zagonel V, Brandi G, Pressiani T, Federico P, Vivaldi C, Bergna I, Campani C, Piscaglia F. Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. Liver Cancer 2021;10:370-9. [PMID: 34414124 DOI: 10.1159/000515551] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
79 Chi Y, Ji G, Zhang J, Tang H, Yang Y, Liu W, Wang N, Gao C, Sun Y, Wang J. Efficacy and safety of anlotinib in patients with advanced malignancy: a single-center, single-arm, phase 2 trial. Int J Clin Oncol 2021;26:1611-8. [PMID: 34297245 DOI: 10.1007/s10147-021-01959-z] [Reference Citation Analysis]
80 D'Alessio A, Prete MG, Cammarota A, Personeni N, Rimassa L. The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges. J Hepatocell Carcinoma 2021;8:177-91. [PMID: 33824862 DOI: 10.2147/JHC.S268310] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]